Clinical Trial News and Research

RSS

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

The VA Maryland Health Care System participated in a landmark national study of more than 10,251 high-risk diabetic adults across the nation, testing if three complementary treatment strategies can reduce the high rate of heart disease and stroke associated with type 2 diabetes and if these treatment strategies can also slow the progression of eye disease associated with diabetes, the leading cause of blindness in working-age Americans.

22 Jul 2010

Valproic acid halts vision loss in patients with retinitis pigmentosa

Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.

22 Jul 2010

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

Ampio Pharmaceuticals, Inc. today announced the initiation of a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus.

22 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

Target Health, LifeOnKey partner to offer web-based information platform to optimize clinical trials

Target Health Inc. and LifeOnKey, Inc. today announced they have joined forces to offer an innovative, web-based information platform that will allow the bio-pharmaceutical and medical device industries to optimize clinical trials, help researchers capture, analyze and assess trial data more efficiently, and bring innovative new medicines and devices to patients.

21 Jul 2010

BioStata invests in KIKA's Veracity advanced EDC platform

KIKA™ Clinical Solutions, the leader in advanced EDC solutions for Clinical Asset Management™, announced that Denmark-based CRO BioStata ApS has made a seven-figure investment in KIKA technology to provide its Veracity™ advanced EDC platform to biopharmaceutical clients in Europe.

21 Jul 2010

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

A microbicide gel containing Gilead's HIV drug tenofovir used by women before and after sex has been shown to reduce their risk of HIV infection by nearly 40%, according to a study unveiled at the International AIDS Conference-AIDS 2010, Reuters reports

21 Jul 2010

Major turning point in antiepileptic drug testing, development

New York University researchers revealed that data from previously completed withdrawal to monotherapy studies for antiepileptic drugs provide a valid control for future studies, obviating the need for placebo/pseudo-placebo trials to demonstrate the efficacy of these drugs as monotherapy. Results of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

21 Jul 2010

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.

21 Jul 2010

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.

21 Jul 2010

New & improved rotavirus vaccine to be trialed in Melbourne

Now a vaccine is being developed against rotavirus in Melbourne. At present Australian children were given rotavirus vaccine at the age of six to eight weeks since 2007. This new vaccine will be applicable to infants from birth.

20 Jul 2010

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced top-line results from a successful Phase 2b double-blind, randomized, placebo-controlled clinical trial of its lead topical pain candidate, ARC-4558, in adult patients with painful diabetic neuropathy (PDN). Arcion recently held an End of Phase 2 meeting with the United States Food and Drug Administration (FDA) and the ARC-4558 program is now poised to enter Phase 3 studies.

20 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its second quarter 2010 results.

20 Jul 2010

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.

20 Jul 2010

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).

20 Jul 2010

Study seeks patients with cancer of oropharynx to participate in Phase I clinical trial of SRS

The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth)) to participate in a Phase I clinical trial.

20 Jul 2010

New report compares efficacy of Plavix, Effient in treating patients with ACS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of acute coronary syndrome, 56 percent of surveyed interventional cardiologists who prescribe Bristol-Myers Squibb/Sanofi-Aventis' Plavix in high doses, consider it to be comparable in efficacy to Daiichi Sankyo/Eli Lilly's recently-launched Effient.

20 Jul 2010

Clinical Trial News and Research

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Valproic acid halts vision loss in patients with retinitis pigmentosa

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

Target Health, LifeOnKey partner to offer web-based information platform to optimize clinical trials

BioStata invests in KIKA's Veracity advanced EDC platform

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

Major turning point in antiepileptic drug testing, development

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

New & improved rotavirus vaccine to be trialed in Melbourne

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Biogen Idec second-quarter revenues increase 11% to $1.2 billion

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

Aegera reports data from Phase 1 portion of combination AEG35156 Phase 1-2 study for primary liver cancer

Study seeks patients with cancer of oropharynx to participate in Phase I clinical trial of SRS

New report compares efficacy of Plavix, Effient in treating patients with ACS

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery